

HEALTHCARE INVESTOR BRUNCH


JANUARY 12, 2025
10:30AM - 1:30PM PST

SAN FRANCISCO, CA

Hosts

Big  Idea
CONNECTpreneur

 opus8



Agenda

Sunday, January 12, 2025

10:30 - 11:30 am - REGISTRATION / NETWORKING

11:30 - 11:45 am - WELCOME REMARKS

JP Morgan Chase & Co. and Opus8/CONNECTpreneur

11:45 - 1:30 pm - NETWORKING

Speakers



TIEN WONG, CEO, OPUS8, INC.

Tien is Founder and Host of the Big Idea CONNECTpreneur Community, a global community of 30,000+ investors, entrepreneurs, business leaders and service professionals. He is CEO of Opus8, an investment and advisory firm which helps tech companies and investment fund managers raise capital. He is also Chairman of Lumious, a leading Ed Tech Company. Tien co-founded and served as CEO of CyberRep, Inc. until its acquisition by ACS/Xerox. CyberRep was one of the largest CRM companies in the world with over 2,300 employees and \$80 million in revenue. Today, the CyberRep/ACS business generates \$3+ billion in revenue as divisions of Xerox, Conduent, and Continuum. He serves on the boards of The Washington Institute for Business, Government & Society; Frederick Innovative Technology Center, Inc. (FITCI); Junior Achievement; Association for Enterprise Growth; and Austin Venture Association. He was appointed by Governor Martin O'Malley to the Maryland Venture Fund Authority which manages \$84 million in venture capital.



MICHAEL SCHWARTZ, VICE PRESIDENT, RELATIONSHIP MANAGER AT JP MORGAN

Michael Schwartz has over 10 years of private banking experience, delivering comprehensive financial advice and services for individuals and business with a focus on Startups and Founders, Venture Capital & Real Estate Investing. Michael received his Master at George Washington University, is fluent in three languages & leans on his multicultural background to provide unique guidance for his clients.

Partners

The logo for J.P. Morgan, featuring the text "J.P.Morgan" in white inside a dark blue circle.

J.P. MORGAN CHASE

J.P. Morgan is a leader in investment banking, commercial banking, financial transaction processing and asset management. We serve millions of customers, predominantly in the U.S., and many of the world's most prominent corporate, institutional and government clients globally. Through continued investments, business initiatives and philanthropic commitments, we aim to help our employees, customers, clients and communities grow and thrive.

The logo for Big Idea CONNECTpreneur, featuring the text "Big Idea" in white and "CONNECTpreneur" in white on a dark blue background.

CONNECTPRENEUR

Founded in 2012, the Big Idea CONNECTpreneur Forum is a global community of over 25,000 CEOs, Entrepreneurs, VCs and angels, CXOs and other business leaders. CONNECTpreneur RocketPitch is the World's Largest monthly investor pitch event, mashing up 600 - 800+ top founders, investors and business leaders featuring awesome networking, newsmaking speakers, and a "Rocket Pitch" showcase of exciting early stage companies. These unique events are like none other due to the high quality of our attendees and participants, as well as our programming and unprecedented networking, which maximizes the experience for all of our attendees and sponsors. The CONNECTpreneur team also provides capital raising, mentorship and support to hundreds of entrepreneurs as well as investors and VC funds around the world.

The logo for Opus8, featuring a stylized orange and yellow insect-like icon to the left of the text "opus8" in a lowercase, sans-serif font.

OPUS8

Opus8 is a private investment firm. We invest in well-run companies in life sciences and tech-enabled services, and also provide high-level fundraising, strategy and business advisory services to clients on a select basis. In addition, Opus8 seeks to acquire well-run companies servicing the healthcare and life sciences industries in BPO, CRM, contact center, and marketing services.

Exhibitors



20/20 GENE SYSTEMS

20/20 GeneSystems, Inc. is a clinical laboratory test developer focused on AI-powered blood tests for the early detection and prevention of cancers and chronic diseases. We are currently the #2 market leader in the U.S. for multi-cancer early detection (MCED) blood tests. Our flagship product, OneTest™ for Multiple Cancers, is seeing rapid adoption in the MCED marketplace with ten consecutive quarters of accelerated sales growth.



ALPHYN BIOLOGICS

Alphyn's first drug candidate for atopic dermatitis (also known as AD and as eczema), Zabalafin Hydrogel, is the forefront of an evolution to treat directly all the problems of AD, treating directly the bacterial cause and exacerbation of AD, along with directly treating itch, inflammation, and infected AD skin that make AD so difficult to manage. In Phase 2a clinical trials Zabalafin Hydrogel demonstrated better results and excellent patient tolerability compared to other drugs suggesting it may be the first AD drug that is worry free for long term and continuous use. And reported in a recently published dermatology paper authored by dermatologist key opinion leaders, Zabalafin Hydrogel may become the drug of choice to treat AD. With its first-in-class Zabalafin Multi-Target Therapeutics™ Drug Platform, Zabalafin's unique multiple bioactive compounds and resulting multi-target benefits are providing Alphyn a deep and rich pipeline of additional new drug products for severe and prevalent skin diseases. Alphyn has the opportunity for a near-term investor liquidity event in the next 18 to 24 months with directly market-comparable liquidity event transactions that support a 17x to 25 x return to new investments.



ASTRO HEALTH

Astro Health is building Astro X - A highly intelligent AI digital health B2B SaaS system with multi-modal data sources utilizing LLMs for real-time mental health, substance use monitoring, real-time personalized evidence-based interventions and increasing work productivity. The US market size for this AI system is >\$1 Trillion which makes it an exciting investment opportunity. Astro Health has an AI research and Deployment partnership with AI Titans University of Southern California's Information Sciences Institute (pioneers of NLP, birthplace of internet, first quantum computing system in academia).

AQUILLIUS

Aquillius Ventures is a women-owned, minority-owned, firm that supports entrepreneurs that are commercializing cutting-edge technologies to improve the health of people and the health of the planet. Our investment strategy is driven by a commitment to equity, with a focus on supporting overlooked technologies and founders, specifically women-led startups. Our core principle centers on prioritizing investments that generate both financial gains and contribute meaningfully to tackling societal challenges, notably in sectors like women's health, children's health, and elderly health. We intend to allocate up to 60% of our investments toward startups tackling these problems.



Exhibitors

Our leadership is spearheaded by two General Partners, Leah Villegas and MyPhuong Le, who are both accomplished scientists, serial entrepreneurs, and seasoned investors. Both hold PhDs in Pharmaceutical Sciences from the University of Florida and bring over two decades of experience in early-stage R&D and therapeutic and device development from prestigious institutions, including the University of Colorado, the University of Washington, Mayo Clinic, and Microtek – a leading medical device manufacturing company. Together, we bring unparalleled scientific rigor, operational expertise, and industry insights to drive transformative innovation.



EVERIX OPTICAL FILTERS

Everix enables mass deployment of compact personal health and technology devices with features that were not affordable in the past. We turn inexpensive polymer into a nanomaterial (optical filter) that is worth 20x the value of GOLD by weight. We make it 10x-100x more cost efficient, 70x more energy efficient, and 20x more compact than our competition. With 37 patents and a full manufacturing operation, we are serving top-tier Fortune 50 customers in markets such as medical devices, consumer electronics or industrial sensing.



i-LUMEN SCIENTIFIC

i-Lumen Scientific has pioneered vision restoration in those with Dry Age-related Macular Degeneration, a disease that affects 1 in 4 people, and is the leading cause of blindness in those over age 60. The i-Lumen AMD system is a non-invasive, office-based therapeutic that delivers low level electrical pulses to improve cellular function within the Retina. i-Lumen has demonstrated unprecedented clinical results with 50% of patients having improved vision of 10+ letters on the ETDRS eye chart within 90-days of treatment. The i-Lumen system is backed by clinical success following its US-based, i-SIGHT Study. In 2025, i-Lumen will start its i-SIGHT2 Pivotal Study, and is well-positioned for US market clearance as a Class II device via De Novo. The Company's retinal and macular disease advisors include Dr. Sophie Bakri, Chair of Ophthalmology at the Mayo Clinic, Prof. Tim Jackson, Head of Retinal Research at King's College UK, and Dr. Jason Slackter, Vitreous Retina Macula Consultants of New York. i-Lumen's leading investors include Bios Partners, MedFocus, and Alafi Capital, and strategic investor, Santen Ventures (venture arm of Santen Pharmaceuticals).

Exhibitors



NEUROEM THERAPEUTICS

The Alzheimer's Treatment Device NeuroEM is commercializing, is a groundbreaking wearable technology that will revolutionize brain health and the treatment of cognitive decline. This first-of-its-kind device offers a safe, effective, and non-invasive approach to treating neurodegenerative diseases, including Alzheimer's disease, and protecting brain health throughout the aging process. The NeuroEM Team envisions a world with hope for millions affected by cognitive decline— from patients battling neurodegenerative diseases like Alzheimer's to people striving to safeguard their cognitive health against the rigors of daily life and the natural aging process. Our mission is to harness the results of a decade of independently validated clinical research demonstrating the power of our technology, TEMT-RF, to stop and even reverse cognitive deterioration. NeuroEM addresses the Alzheimer's market and the brain health market, which totaled \$210.65B in 2022 and is expected to surpass \$455.2B by 2032. The US market for consumer brain health devices alone will reach \$15B in the next five years. The company is raising a \$5M Series Seed/A round.



20/20 GeneSystems, Inc.
15810 Gaither Dr., Suite 235
Gaithersburg, MD 20877

www.2020gene.com
www.OneTestforCancer.com

Key Strengths:

- Our approach is substantially more **affordable, accessible, and accurate** for early-stage cancer detection than the leading DNA based MCED on the market.
- 2023 Inc.5000 Fastest Growing Company in Maryland.
- Strong patent position covering screening w/ machine learning + tumor antigens.
- Utilizes FDA approved instruments and kits.
- Pilot w/ leading supermarkets.
- Sophisticated Shareholder Base: Including DigitalDx, Fujifilm (via acquisition), PingAn Ventures, Morgan Stanley (via Acquisition), Brevet Capital, Keiretsu Capital, and leading Family Offices.
- Board and management team have many successful exits.
- IPO ready w/ PCAOB audits and other compliance in place; engagement with reputable investment bankers
- Periodic acquisition inquiries from Fortune 500 industry leaders.
- Growing revenues permit royalty-based financing models w/ guaranteed ROI.

Contact:

investors@2020gene.com
 (240) 453.6339 ext. 102

Executive Summary

20/20 GeneSystems, Inc. is a clinical laboratory test developer focused on AI-powered blood tests for the early detection and prevention of cancers and chronic diseases. We are currently the #2 market leader in the U.S. for multi-cancer early detection (MCED) blood tests. Our flagship product, ***OneTest™ for Multiple Cancers***, is seeing rapid adoption in the MCED marketplace with **ten consecutive quarters of accelerated sales growth**.

The Problem: Screening is not widely available or utilized for most of the leading cancer killers, such as those of the lungs, pancreas, ovaries, and liver. To address this void, MCEDs are now available and generating significant enthusiasm among many medical authorities, policymakers, employers, and consumers. Up until now, these tests have been expensive, hard to access, and miss most cancers at their earlier stages when they can often be effectively treated.

Our Solution & Advantages: *OneTest™* is the first and only MCED on the market that (i) is available for under \$200, (ii) can be accessed at home without painful needles, and (iii) has been demonstrated in studies conducted in 2024 by the U.S. National Cancer Institute to correctly identify significant numbers of otherwise deadly **cancers at an early stage**. These cancers include those of the lung, pancreas, and ovaries, which, when detected at an earlier stage, give the best chance of survival. (Supporting data available upon request.)

The MCED Market is Projected to be +\$2B by 2030: In the U.S. alone, the market for MCEDs is expected to exceed several billion dollars per year by the end of this decade following anticipated coverage by Medicare starting in 2028.

Our Progress:

- #2 MCED Player, revenue doubling every 6 months with 10 consecutive quarters of increasing sales growth
- Over 18,000 tests sold from 2022-2024 to date
- Line-of-sight to profitability
- Growing adoption among employers and consumers
- Additional revenues already coming from SaaS license agreements w/ clinical testing laboratories in Taiwan and Japan

New Product: AI-powered ***OneTest for Longevity*** will track biomarkers of chronic inflammation associated with 8 of 10 leading causes of death and offer specific diet and exercise changes proven to lower biomarker levels and related disease risk.



Alphyn Executive Summary

Breakthrough Drug of Choice for Atopic Dermatitis (Eczema)

Multi-Target Therapeutics™
A New Class of Drugs
More Powerful Therapeutics

MANAGEMENT TEAM

Neal Koller – Chairman & CEO
President & CEO, Board of Directors, life science businesses, **last exit at 16x**; Sr. Exec. Wyeth

Steven Pentelink – President
P&G Exec. managed **\$1B early tech portfolio**, global manager \$750M Beauty Care Products

Gary Pekoe, PhD - Chief Scientific Officer
Director for several multinational pharma companies, led development & approval of 1st & market leading topical antibiotic **Bactroban®**, lead clinical trial protocol writer for **Keytruda®**, 20 years clinical and regulatory adviser to pharma

Jazmyne Mink – Regulatory Affairs Manager
8 years' experience with Alphyn's AB-101

OPERATIONAL PARTNERS

Eagle Analytic - Analytics Lab
Emery Pharma - Chemistry & Microbiology Lab
World Class Ethnobotanist
World Class Botanical Chemistry & Analytics Lab
DDL - Formulation and Manufacture
PCCA - Formulation and Manufacture
Multiple Geo-local Agri Partners
TagOne - Supply Chain Management
Accelagen - Regulatory and Clinical Trials (AUS)
Symbio - Regulatory and Clinical Trials (US, EU)
DLA Piper - IP and Legal Worldwide
EisnerAmper - Finance and Tax (US)
Artus GmbH - Finance and Tax (EU)
RDI Partners - Finance and Tax (Australia)

SCIENCE ADVISORS

12 Global KOL Dermatologists

Dennis P. West, PhD
Prof Emer, Derm, Feinberg Sch of Med, Northwestern Univ

Peter Coderre
FDA IND & NDA Microbiology Reviewer (retired)
Scientific Advisory Board, CARB-X (BARDA, NIAID, NIH)
Antimicrobial Regulatory Consulting LLC

Patric Lundberg, PhD
Past Associate Prof, Microbiology/Molecular Cell Biology
Eastern Virginia Medical School

Shekhar Mitra, PhD
Sr VP, Global Innovation, Procter & Gamble (retired)
President, InnoPreneur, LLC

FUNDING TO DATE

Founders \$ 870 K (not capitalized)
Seed \$ 1.1 M (Convertible Note)
Pre-equity \$ 2.5 M (Convertible Note)
Series A \$ 5.5 M (Series A)
Non-dilutive \$ 2.1 M

CURRENT SERIES B FINANCING

Series B \$18.0 M; **\$8 M raised**
2 liquidity event milestones funded
Lead Investor in place, diligence available

SERIES B's 4 EXIT LEVEL MILESTONES

FUNDED - Complete Phase 2b AD Trial in AUS
FUNDED – Increase to \$2.7B drug raw material asset
Complete Phase 2b AD Trial in US & EU
Complete 2nd drug Phase 2 Trial

COMPANY OVERVIEW

Alphyn is using its zabalafin (AB-101) drug platform to develop immuno-inflammatory topical therapeutics with fewer side effects, greater patient tolerability and that are more effective, initially for Atopic Dermatitis (AD), followed for Epidermolysis Bullosa (EB). Zabalafin is a new class of drugs named Multi-Target Therapeutics™ providing unique multiple mechanisms of action from multiple bioactive compounds for multiple ways to treat an individual disease, to be more effective, and multiple diseases to treat. Alphyn's 1st drug candidate, topical zabalafin hydrogel, completed 2 Phase 2a clinical trials in AD, a huge AD commercial opportunity. Clinical results better than competitive drugs point to "drug of choice" for this vast \$118 Billion market⁵ with reported 800 million patient population¹. Alphyn submitted the Investigational New Drug (IND) application to FDA requesting start of the Phase 2 clinical trials for AD in the U.S., projected to start January 2025. The Company has US patent protection to 2042 with global applications in process. Powerful new published paper by KOL dermatologist influencers support zabalafin as drug of choice for AD

THE PROBLEMS IN TREATING AD

- 60.5% of adults report severe itch, 55 % report inadequate disease control²
- 67% of children and 33% of adults report poor quality of life²
- 8.3-year life reduction with hospitalizations primarily due to AD bacteria-associated problems³

TWO SUCCESSFUL PHASE 2a CLINICAL TRIALS: ZABALAFIN ADVANTAGES

- Most important - itch superior to competition
- Only AD drug to directly treat itch and the critical Bacteria Component of AD
- 90% of patients report significant improvement in Quality of Life
- 35% better reduction in inflammation versus dominate market leader (IGA)
- Side effect reduction and patient tolerability superior to competition
- Strong safety data resulted in: Waiver of Phase 1 clinical trial; Phase 2 clinical trials start age 2
- **Clinical results point to 'Drug of Choice' for AD**



MULTIPLE MARKET PROTECTION STRATEGIES

- US patent protection to 2042: US & Global Filings, Composition of Matter, Methods of Use
- Regulatory exclusivity possible: 10 years USA, 8 years Europe & Japan
- No FDA generic drug competition possibility
- Estimated 15 year robust drug raw material supply protection: Quantity, Contracts, Regulatory

VAST AND GROWING AD MARKET

Drug (Company)	Time on Market	Annualized Sales ⁴	Estimated Patient # ⁵
Dupixent® (Sanofi)	4 years	\$7 Billion	~ 270,000
Opzelura® (Incyte)	2 years	\$556 Million	~ 151,400

AD STRONG COMPARABLE EXIT DEALS

Acquired / Licensed	When	Exit: Cash plus Milestones	Exit Stage
Proteologix (by J&J)	May '24	\$850 Million + Milestones	Pre-clinical
Kyowa Kirin (by Amgen)	Jun '21	\$1.25 Billion	Phase 2 clinical trial
Kymab (by Sanofi)	Jan '21	\$1.45 Billion	Phase 2 clinical trial

ASTRO X – A Highly Intelligent AI Digital Health Platform for real-time Mental Health monitoring, Stress Support and enhancing Workplace Productivity via Multi-modal data sources utilizing Large Language Models (LLMs)

- Improving outcomes, generating cost-savings and increasing productivity

According to the National Institute for Occupational Safety and Health (NIOSH), between 26% to 40% of the workers in the US report extreme work-related stress¹ while ~85% of the employees report experiencing some amount of Stress.² Workplace Stress costs US employers \$300 billion dollars/yr due to high turn-over rate, absenteeism and increased healthcare costs in employees with Stress. Stress is known precursor for depression, anxiety, alcohol misuse and substance use disorder.

Solution: Astro X – A Highly Intelligent AI Digital Health Platform

- **Multi-modal data (social, environmental, work, physiological biomarkers (sleep, physical activity, heart rate, eye tracking), conversational AI and social media data)**
- **LLMs to analyze and detect harmful behavior**
- **Clinically validated assessments**
- **Real-time Remote Monitoring of stress and on-set of depression, anxiety and Substance Use**
- **Real-time Support to address the exact causes of stressors**
- **Human-in-loop (licensed therapists) for extreme stress management**

Strategic AI research partnership with University of Southern California’s Information Sciences Institute – the AI Titans in the field.



INVESTMENT OPPORTUNITY

1. US TAM \$300 Billion with target 5% SOM of \$15 Billion
2. AI research partnership with No.1 institute in the US for artificial intelligence
3. High fidelity exceptional co-founding team with deep expertise in AI, ML, Digital Health, Outcomes and Behavioral Sciences
4. B2B SaaS business model with M&A or IPO exit strategy. Investor ROI projected ~600x over 10 yrs.

SEED FUNDING REQUESTED:

- \$3.5 million dollars via YC SAFEs**
18 months run-way to cover:
- Salaries + 2FTEs
 - USC AI Research Partnership
 - B2B Pilot program implementation

Contact:

Shraddha Chaugule, PhD
 Founder, Astro Health Inc
 Address: 1 Sansome St., Suite 3500, San Francisco, CA 94104
 Email: shrads@astrohealth.ai

¹ CDC Available at: <https://www.cdc.gov/niosh/docs/99-101/default.html>

² <https://www.osha.gov/workplace-stress>



Executive Summary

Aquillius Ventures' Fund I is a \$50M VC fund based in San Diego, CA focused on early-stage Med Tech and Life Sciences startups. We are looking to invest in pre-seed and seed rounds for startups based in the US.

Our **mission** is to improve human health and create a healthier planet, specifically by focusing on women, children, and the elderly.

What makes us unique

Over the past two decades we have developed the infrastructure to attract, develop, and scale startups from early stage to market-ready.

Our vertical integration allows us to have visibility on development, risks, and go-to-market strategies.

Fund

Size: \$50M
 Term: 10 years
 Inv. Period: 5 years
 Min. Investment: \$500k
 Terms: two and twenty

Portfolio

Total Investments: 40
 Investments per year: 10
 Avg. Portfolio Inv.: \$500k

Returns and Equity

IRR Range: 15% - 20%
 MOIC Range: 4X - 6X
 Target Equity: 10% - 25%

Everix Inc.

City, State: Orlando, FL
 Phone: (407) 923 - 3260
 Website: www.everixopticalfilters.com
 CEO: Hooman Banaei, PhD.
 Email: hooman@everix.co



Everix enables mass deployment of compact personal health and technology devices with features that were not affordable in the past. We turn inexpensive polymer into a nanomaterial (**optical filter**) that is worth **20x the value of GOLD by weight**. We make it **10x-100x more cost efficiently, 70x more energy efficiently, and 20x more compact** than our competition. With **37 patents** and a full manufacturing operation, we are serving top-tier **Fortune 50 customers** in markets such as medical devices, consumer electronics or industrial sensing.

Problems

1- Filter size limits product miniaturization and sensor sensitivity; 2- Rigid form-factor; 3-Insufficient economies of scale for mass markets. Current manufacturing technologies have hit an innovation plateau despite many unmet needs.

Technology & Products

Technology: To meet the need for lower-cost, high-volume optical filters, we have developed a process that replaces traditionally expensive vacuum deposition with a much less expensive thermal drawing tower. Like the process for drawing glass optical fibers from cylindrical preforms, we create planar preforms and draw the layers to sub-wavelength thicknesses needed to create any desired interference filtering effect.

Product Lines (filters): Notch, Bandpass, Dichroic, Edge, Absorptive, Hybrid. Products currently sold via distributors or directly to customers.

Unique Value Proposition

Device miniaturization (e.g., smart watches); New form factors (e.g., ingestible sensing capsules); Enabling price-elastic markets (e.g., home-based personal infection/cancer testers); Short lead time for high volume (time sensitive consumer electronic product release); Freedom of material choice (to meet application-based requirements).

Business Model

1- Sales of standard products in beachhead markets directly and through multiple sales channels. (markets: medtech, sensors).
 2- Sales of customized products to key players in AR/VR. (markets: AR/VR, consumer electronics)
 3- IP licensing in other markets (markets: eyewear, smart glass, solar control, solar generation, display/cinema).

Competition

Everix has a unique, patented technology, which fills the gap between:
 1. Traditional vacuum coating companies, all using patent-expired technologies (Viavi Solutions, Materion, Semrock, Alluxa, Omega, Chroma).
 2. Multilayer film extrusion industry – primarily for non-filter applications and low-performance filtering (such as display back-reflectors) due to process nature limitations (3M, PeakNano, Toray).

Investment Opportunity

Current Round: **\$3M bridge to profitability** round. Approx. 50% invested or committed.

Use of funds

Reaching operational profitability, new hires, strategic IP portfolio expansion, working capital for consistent production of standard products, boosted sales and marketing of standard products into beach head markets, continued IP protection.

Team

Hooman Banaei, PhD, CEO/Founder – Optics PhD. Family manufacturing business with 500 employees.

Jess Brown, PhD, Sales & Business Development Director - 20 years in sales and business development in optics and electronics industries.

Andy Moyle, Director of Operations - 8 years in manufacturing improvement and management.

Karolina Wojtas, Director of Strategic Development - 5 years in VC, 3 years of operational experience in startups, ex-founder.

Market

TAM: **\$50B+**
 Beachhead emerging markets: Consumer Medtech (\$1.6B), Consumer Electronics (\$4.3B) IoT and Automotive sensors (LiDAR, etc.) (\$2.5B)
 Future blue ocean markets: eyewear, smart glass, solar control, solar generation, display/cinema.

Financials

Revenue: 7-figures cumulative revenue from initial product sales and PoC. Fortune 50 paying customers.

VALUE PROPOSITION:

Restoring Vision, Not Just Managing Disease: 50% of patients improve vision by 10+ letters within 90-days.

Huge Market Opportunity: 130.0 Million are afflicted with Dry-AMD and projected market value of \$68.5 Billion by 2029.

Derisked Investment Opportunity: Backed by US-based feasibility study and well-positioned for Class II De Novo clearance

Rare Exit Potential in Ophthalmology: Comparable acquisitions have yielded 12-15x returns in 3-4 years.

Company Background: Ophthalmology company that has pioneered ‘Vision Restoration’ in those with Dry Age-related Macular Degeneration (*Dry-AMD*).

Leadership Team: Senior Management team has led FDA clearance for 16 Class II and III technologies and held leadership roles in 5 companies that have been acquired and delivered \$850.0 million in shareholder value.

Scientific/Medical Consultants: Dr. Sophie Bakri, Chair of Ophthalmology at the Mayo Clinic, Prof. Tim Cackson, Head of Retinal Research at King's College UK, and Dr. Jason Slackter, Vitreous Retina Macula Consultants of New York, and Robert Warner (Former President of the Americas, Alcon).

Products/Services: The level electrical pulses through an electrodes placed on the eyelid and the back of the neck to improve cellular structure and function within key cells of the Retina – included Retinal Pigment Epithelial and Ellipsoid Zone.

Technologies/Special Know-How: i-Lumen’s proprietary dual waveform algorithm and treatment delivery system generated unprecedented clinical benefit within 90-days of treatment as 50% of patients had improved vision of 10+ letters on the ETDRS eye chart.

Market: The global market opportunity is valued at US\$44.6 Billion in 2025 and is projected to reach US\$68.5 by 2029. AMD is the leading cause of blindness in those over age 60 and it affects 1 in 4 people. Globally, more than 130 million people have AMD.

Distribution Channels: i-Lumen’s highly scalable business model represents an incremental revenue stream for Ophthalmology offices. The Medicare reimbursement rate for daily treatments is projected to be between \$1,000 to \$1,400. Coupled with clinical results, reimbursement will drive adoption and utilization.

i-Lumen will leverage a Lasic vision correction surgery revenue model – ‘pay per treatment’. An electronic key provided for each treatment delivered will automatically invoice (\$400 per treatment) the physician practice. The device system is capital equipment and has a gross margin of 90%.

Competition: The treatment solutions available today, including Syfovre (Apellis) and Izervay (Astellas), which only slow the progress of the disease while vision loss continues. Unfortunately, these intravitreal injections have side effects that could include inflammation within the eye and advancing patients into late-stage, wet-AMD.

Exit Strategy: Acquisitions in Ophthalmology are generally pre-revenue and yield 12-15x returns. i-Lumen has initiated conversations with leading industry strategics (Alcon, Johnson&Johnson, Carl Zeiss, and Bausch&Lomb) regarding acquisition of the technology. Clinical data to support market clearance is projected in 3-4 years.

Quick Facts

Company Name:
i-Lumen Scientific, Inc.

Contact:
John VeLure (CEO/President)

Address:
3800 American Blvd. West
Ste. 1500
Bloomington, MN 55431

Phone: 952-240-6023
Email: jvelure@i-lumen.com
Website: www.i-lumen.com

Industry: Ophthalmology

Domain: Medical Device

Bank: Minnesota Bank & Trust

Law Firm: Fox Rothschild

Patent Estate:
Fox & Rothschild
29 US Patents, 3 CN Patent, 3 EU Patent, 2 AU Patent

Auditor: Baker Tilly US, LLP

Number of Employees: Seven (7)

Leadership Team:
John VeLure (CEO/President)
Meredith Mundy (Research)
Tracey Henry (Regulatory)
Thu-Ha Duncan (Manufacturing)

Amount of Financing Sought:
\$22.0 Million

Current Investors:
Bios Partners, MedFocus, Alafi Capital, and Santen Ventures

Use of Funds: Pivotal Study and FDA Market Clearance

Deal Terms:
Series B Funding Round
Convertible Preferred Stock
8.0% Cumulative Dividend
Liquidation Preferences
Anti-Dilution Provision
Share price: US\$1.35

Valuation:
Pre-money: US\$31.5 Million
Post-money: US\$55.6 Million

Participation Options:
Direct Investment: US\$500K min.
Bios SPV: US\$50K min.



NeuroEM's first-of-its-kind device offers a safe, effective, and non-invasive approach to treating neurodegenerative diseases, including Alzheimer's, and protecting brain health throughout the aging process.

www.NeuroEM.com

Alzheimer's is among the costliest conditions to society

- Worldwide, **55M people** are living with Alzheimer's.
- Nearly **7M Americans** have Alzheimer's. **500,000 more** are diagnosed each year.
- Medicare spends 3 times more** for beneficiaries with Alzheimer's.

NeuroEM will be a disruptive force in the Alzheimer's therapeutics market

There is no cure and treatment options are ineffective and difficult for patients and cost thousands of dollars per year.

- 5 of the 8 FDA-approved drugs do not affect the underlying brain changes that cause symptoms. **None are right for all patients.**
- Ongoing research exploring potential pharma options **remains uncertain.**


Human clinical studies showed cognitive stabilization or improvement in 7 of 8 AD sufferers within 2 months

Our Transcranial Electro-Magnetic Treatment using Radio Frequencies (TEMT-RF) alters three key factors at the root of cognitive decline:

- Detoxify the brain by disaggregating toxic Aβ and p-tau proteins
- Rebalance cytokines, indicating a reduction of inflammation in the brain and body
- Increase ATP—the source of energy for use and storage at the cellular level

Capital investment to date: \$7M+

Target Milestones



Investment Opportunity

NeuroEM is raising two rounds over the next two years:

- \$5M Seed Preferred today** to prepare the final product for launch; Target pre-money valuation: \$15M
- \$5-10M Series A Preferred in 2025** to launch the wellness product; Target pre-money valuation: \$30-45M

GLOBAL MARKET

ALZHEIMER'S THERAPEUTICS

\$4.05B
IN 2022

\$30.8B
IN 2033

DIGITAL BRAIN HEALTH

\$200B
IN 2022

\$413B
IN 2032

NOOTROPICS / SUPPLEMENTS

\$6.6B
IN 2022

\$11.4B
IN 2031

FROM RESEARCH TO COMMERCIALIZATION:

NeuroEM is transforming groundbreaking research into a commercially viable reality.

10+ Years of University Research

2 NIH Grants + More in progress

Patent portfolio includes **9 issued US patents** and **10 pending patent applications globally**

First to receive **FDA Breakthrough Device** status for the treatment of Alzheimer's

A **proven leadership team** and **medical advisory board** – all with a scientific or technology background, startup experience, and commercial expertise.

Startup Health **Alzheimer's Moonshot Community** Member



Contact

Chuck Papageorgiou, CEO
Chuck@NeuroEM.com
+1-727-252-6120

January 12 Attendees As of 01 12 25

EXHIBITORS			
First Name	Last Name	Title	Company
Jonathan	Cohen	CEO	2020 Gene Systems
Neal	Koller	Chairman and CEO	Alphyn Biologics, Inc.
Leah	Villegas	Managing Partner	Aquillius Ventures
MyPhuong	Le	General Partner	Aquillius Ventures
Shraddha	Chaugule	CEO	Astro Health Inc
Hooman	Banaei	Founder and CEO	Everix Optical Filters
John	Velure	CEO and President	i-Lumen Scientific, Inc.
Michael	Schwartz	Vice President	J.P. Morgan Private Client
Chuck	Papageorgiou	CEO	NeuroEM Therapeutics Inc.

ATTENDEES			
First Name	Last Name	Title	Company
Anupam	Agarwal	Senior Vice President	Denovo Biopharma
Smriti	Agrawal	Angel Investor	TiE Angel Houston
Anish	Aitharaju	Principal	DigiTx Partners
Ali	Al-khattawi	CEO	MESOX
Zaheer	Ali	COO	Positon AI
Rebecca	Allan	Investment Manager - BoxOne VC	BoxOne Ventures
Scott	Alpizar	CEO	Pinco Biotherapeutics
Andrew	Altschuler	Partner	AAA FO
Mark	Amouzgar	Partner	March
Goldein	Anatoly		
Jolene	Anderson	Managing Director	VectorPoint Ventures
William	Annett	CEO	Sustained Therapeutics
Marc	Appel	Managing Partner	Pacific Bridge NY
Joshua	Armah	Managing Director	Armah Ventures
Maria	Artunduaga	CEO	Samay
Trishan	Arul	CEO	Picture Health
Katie	Austin	Venture Partner (OD)	GSC360
Bob	Austrian	Executive Director	J.P. Morgan Wealth Management
Julianne	Averill	Advisor	How Women Invest
Joachim	Bader	Managing Director	Noble Capital Markets
Ron	Baker	Chief Business Officer	2020 Gene Systems
Aparaajita	Balaji	Associate	KB Investment
Julie	Ballard	Principal	Carrot Clinical
Alexander	Ballatori	Cofounder & CEO	StrokeDx, Inc
Michael	Banyas	Program	National Institute of Minority Health
Josh	Barer	Managing Director	Hibiscus Capital Management
Amir	Barsoum	Founder and Managing Director	InVitro Capital
Kenneth	Barton	CEO	SafetySpect Inc.
Rene	Baston	Venture Partner	Covenant Venture Capital
Pierre Henri	Belin	CEO	Xcube.bio
Jenny	Belotserkovsky	Co-Founder and CEO	MenHealth
Cigdem	Benam	Porfolio Executive	Innovation Works
Joshua	Benig		
Stephane	Berthier	CEO	SDK Therapeutics
Vikash	Bhagwandin	Founder & CEO	VincaStemx
Nilesh	Bhandari	CEO	Advanced Health Academy
Payal	Bhandari		Integrative Functional Medical Physician
Urvashi	Bhatnagar		
Jake	Bieber-Dishart	Analyst	Apple Tree Partners
Bob	Bloom	CEO	RBI
Eve	Blossom	Founder	Material Change Institute
Jose	Bolanos	CEO	Nimbus-T Global inc
Diane	Bouis	US Director	MedTech World
Greg	Bowman	Senior Director, Leasing	Breakthrough Properties
Beckie	Bown		
J.	Bradley	Founder	TAN
Lily	Bragg	Chief Fixer	Wave Operator
Robert	Brooks	CEO	Radiance Biopharma
David	Buller	Managing Partner	Keles Digital Health
Ross	Bundy	CEO	CRISPR QC, Inc.
Nathan	Cali	Managing Partner	Noble Capital Markets
Heather	Callahan	CEO	Allander Biotechnologies
Hanne	Callewaert	CEO	AstriVax
Ian	Campbell	CEO	TendoNova
Taylor	Caparosa		Savills
Christian	Carello	Founder, CEO, + Angel Investor	EnvisionIt Consulting, LLC

Sofia	Carvalho	Founder & CEO	SecretBox
John Michael	Cataldi	Manaing Partner	Native American Venture Fund
Lisa	Cavallaro	Senior Manager - Investment	Brisbane Economic Development Agency
Jeff	Cazeault	Global Advisor, Life Sciences	Biozom Global
Tyler	Chan	Physician	Emory
Rishikesan	Chandrakumar	Senior Associate, Corporate Development	Tenaya Therapeutics
Shraddha	Chaugule		
Shailesh	Chavan	Managing Partner	Transatlantic Life Sciences Ventures
Ephrem	Chedid	Co-Founder & CRO	Klaim Inc
Caifu	Chen	President	3DMed Diagnostics USA
Yutao	Chen	Senior Investment Manager	Shanghai Healthcare Capital
Kelly	Cheng	US Digital Health Strategy	Samsung
Peikwen	Cheng	Co-Founder and CEO	Yiviva
S. Chakra	Chennubhotla	Chief of AI, COO, & Co-founder	PredxBio
Olga	Chervyakova	CEO	MK resolutions
Winsome	Cheung	Partner	Covington
MJ	Chey	CEO	Integral health
Cheryl	Chin	VP Marketing	Exai Bio
Lynn	Cho	Senior Manager	Mint Venture Partners
Lucy	Chong	Associate / Sr. Associate	Fine Structure Ventures
Daphne	Chu	Partner	ActionSpot Startup Studio
Alicia	Chung	Venture Advisor	Magnet Ventures
Alex	Chung	Partner	Sheppard Mullin
Craig	Cinquina	Chief Commercial Officer	PredxBio
Craig	Cooper	Partner	Serpentine Ventures
Jason	Cosman	Senior Director	3DMed Diagnostics USA
Brian	Cowley	VP BD	Think-Now
David	Craig	Founder and CEO	Sarcomatrix Therapeutics Corp.
Bonnie	Crater	CEO	Vignabio
Juan Cruz	Cuevas	Venture partner	Sf500
Ben	Cyrolnik		
Darryl	D	Principal	DH & Assocs. BBREI
Han	Dai	Chief Innovation Officer, Head of Investment	Viva Biotech
John	Dalton	Partner	Blends
Yogesh	Dayma	Veture Partner	1004 Venture Partner
Gilles	de Bordeaux	CIO, Vice-President	Smart Bumper Sticker, Inc.
Anders	de Joungue	Managing Director	Sutter Securities ,Inc.
Margot	DeFrance		
Stephanie	Del Bianco		
Ben	Delhey	CEO	BOYDSense
Jessica	Dennison	Research Analyst	Collage Venture Partners
Jerome	Deval	Head of Discovery	Bluejay therapeutics
Abhinav	Dey	Senior Associate	RM Global Partners LLC
Raghu	Dhulipala	Co-founder	Sympti
Reig	Diamond	Director	Fitumit Consulting
Maggie	Dore	Director	Breakthrough Properties
Roman	Doronin	CPO	Optic
Vishal Chetankumar	Doshi	CEO	AUM Biosciences
Noah	Doyle	Managing Director	Javelin Venture Partners
Christoph	Dressel	CEO	Mimo.fit
Ron	Drummond	Director of Sales	Aquillius
Cecile	Dupont		
Chris	Durbin	Broker	Voit Real Estate Services
Jake	Edick	CEO	Magsorbeo Biomedical
Amit	Eisinger	Consultant	SyzOnc
Medhat	El Masry		
Jonathan	Ellis	Managing Partner	InnovateHealth Ventures
Martin	Erim	CEO	First Renaissance Ventures
Wei	Escala	CEO	Eggschain, Inc.
Caroline	Fairbank	Sr Associate	Initiate Ventures
Abdallah	Falou	CTO, Cofounder	
Emily	Fang	CEO	InFocus Therapeutics
Gregory	Fanning	CDO	AstriVax
Alex	Farren	CEO/Founder	Mynatek
Stefanie	Fasshauer	Director Business Development	Cisema
Lora	Feng	Partner	Hongling Capital
Michael	Fenn	Venture Partner	Iaso Ventures
Frank	Ferrara	Venture Capital Advisor	GSC360
Keith	Finman	Cheif Medical Officer	SensTek
Mark	Fitchmun	CEO	Somatek
Collin	Flintoft	GTM Strategy	Google
Bridget	Flood	Senior Analyst	Aldrich Capital Partners
Jack	Florio	Life Sciences Investor	NuFund Ventur Group
Max	Forgan		

Yuanyuan	Fu	Investment VP	Shanghai Healthcare Capital
Robert	Galemmo	Principal	Robert Galemmo Consulting LLC
Tarrell	Gamble	Trustee	Alameda County Employees Retirement Assoc.
Robin	Gao	Principal	Sixty Degree Capital
Carolina	Garcia Rizo	Partner	Evexia Biofund
David	Garner	Operations	Venture Black
James	Garofalo	Cofounder/CEO	Lokiten Behavioral Health
Nikita	Gaurav	Venture Partner	Necessary Ventures
Maya	Gervis	Private Wealth Advisor, Director	BMO
Kyle	Giesler	Co-founder CSO	InFocus Therapeutics
Rick	Gilchust		Vannadium
John	Gilstrap	Assistant Secretary	Maryland Dept of Commerce
Gregory	Glenn	CEO	Pinion Immunotherapeutics
Chin	Goh	Director	Tuta corp
Anatoly	Goldin	CIO	CTR
Gary	Goldman	Founder & CEO	Global Health Impact Network and Funds
Miguel	Gonzalez Canudas	Co-Founder and Chief AI Officer	PentaBind
Amado	Gorospe	Research Assistant Pharmacology	Blue Sky Software Ltd
Laurie	Gould	Attorney	AG
Kannan	Govindarajan	Co-founder/CEO	ThetaRho.ai
Anshu	Goyal	CEO	XYone Therapeutics Inc
Mark	Griffin	SVP, financial planning and analysis	Amsurg
Desmond	Grimes	Sales Manager	InfoPathways
Ken	Grise	Principal	Sixty Degree Capital
Kees	Groen	CDO	Matisse Pharmaceuticals B.V.
Titan	Gu	Principal	Gu Family Trust
Shalini	Guda Padmanath	Founder & CEO	SynergiX
Vishal	Gulati	Managing Partner	Recode Ventures
Dahai	Guo	CEO	Zennova Pharmaceuticals Group
Yongqi	Guo	Partner	Shiyu Capital
Anurag	Gupta	CEO	Tembo Health
Rajiv	Gupta	Founder	Buying Simplified
Amer	Haider		Amerhaider
Irtaza	Haider	VC Fellow	OMX Ventures
Darya	Hajimousa	Specialist	UCSF
Christopher	Hall	Managing Director	Marula Health
Christian	Haller	President	Keiretsu Forum Richmond
Mehran	Hamidi	CEO	Protected Wellness
Lu	Han	Partner	Lumira Ventures
Cara	Harbor	Venture Partner (Investor Relations)	GSC360
Susie	Harborth		
James	Harris	General Partner	Global Catalyst Ventures
Quamrul	Hassan	Director	Biotech
Youssef	Helwa		
Nicholas	Henderson	VP	Global Health Impact Fund and Network
Adam	Henderson	COO	Keiretsu Forum
Laura	Holberger	Co-Creation Architect	Novo Nordisk Bio Innovation Hub
David	Homan	Advisor	AAA Family Office
Margaret	Hsiao	Advisor	Amkey Ventures
Lisabeth	Hsu		
Jessica	Hu	CEO	Gene Bio Medical
Sonia	Hunt	Founder	Sonia Hunt
Stuart	Hwang	Venture Partner	Remiges Ventures
Dan	Idzkowski	Managing Partner	AMPP Capital
Valentina	Iosifovna	CEO	MK resolutions
Sudhir	Ippagunta	MD	Fincelera Capital Advisors
Tatz	Ishimaru	Research Acientiat	Endotgerapeutics
Amanda	Iwuagwu	RN	Kaiser permanente
Eswar	Iyer	CEO	Aikium Inc.
Marcel	Jacobs	CEO	Matisse Pharmaceuticals B.V.
Sam	Jahanmir		
Ryan	James	CEO	Dopl Technologies
Gauri	Jaswal	Investment Associate	Overlap Holdings
Hassan	Javanbakht	CSO	Bluejay Therapeutics
Subbarao	Jayanthi		
Lili	Jeffers	Executive Assistant	JP Morgan
Sherry	Jiang	President	American West Pacific Int'l Investment Corp.
Angela	Jimenez	Physician Investor	Leon Health
Haihong	Jin	Chief Scientific Officer	Vitsgen Therapeutics
Alvin	Jogasuria	Investor	ABC
August	Johnson	VC Analyst	Aquillius
Vinod	Joseph	Investor	Samsung
Nicole	Ju	Co-Founder & CRO	Arterios
Mo	Kagalwala	Venture Partner	Aquillius Ventures

Julian Scott	Kaha Kahn	Founder	The Good Science Fund
Gautam	Kainth	Partner	Alykomed Global Solutions, LLC
Theodore	Kalem	President	TCP Health Ventures
Shaan	Kamal	Head of Operations	HRA Capital
Kyunggho	Kang	Creative Director	Orchestra Bio
Pin	Kao	Chief Technology Officer	VSPHarmtech Co., Ltd.
Giselle	Kapoor	CEO	3DMed Diagnostics USA
Rosa	Kaviani	Cofounder	Stealth Startup
Bhavneet	Kavr		Peppers
John	Kennedy		
Keith	Kennerly	CEO	PayRx, Inc.
David	Kerns	Director of Research	Janco Investment Solutions
John	Kettle	Partner	Exintech Pty Ltd
Zoya	Khan	CEO	Raya Health
Gary	Kiang	CFO	Xyla Holdings LLC
Cyprian	Kibura		
Ted	Kim	Director	RM Global Partners LLC
Sharon	Kim		
Byungchan	Kim	CTO	NeuroLambda Therapeutics
Rachel	Kim		
Bianca	King	Associate	SIC Venture Studio
Ravi	Kiron	MD	Biopharm Strategy
Kimberly	Klein	Chief Business Officer	T-Neuro Diagnostics
Yongho	Ko	Patent Attorney	Korea University
Tara	Kochis	Founder	Collective Minds
Vince	Kohli	Global Impact Capitalist	Design Innovation
Kimberly	Kolt	President	For Good Ventures
Jill	Konowich	Director	Health Innovation Capital
Ron	Koo	Investor	
Markus	Krohn	CTO	Immungenetics AG
Cheryl	Kuai	Managing Director	Sixty Degree Capital
Lambert	Kuk	Chief Investment Officer	KB Investment
Junghwan	Kwon	President for Research & Bus. Foundation	Korea University
Christoph	Laechler	Partner	CMS Hasche Sigle
Gaele	Lalahy	COO	Plexaa
Nathan	Langley	CEO	RxGuardian Inc.
Nathanaël	Langlois	CEO	Blends
Adam	LaPrad	COO	SurgiVance, Inc.
Frank	Lau	Angel Investor & Co-Founder	TiE Angel Houston
Winnie	Lau	Investor	Novilla Pharmaceuticals, Inc.
Robert	Lauritzen	CEO	Cerebriu
James	Lee	Managing Director	Vertex Growth Fund
Raymond	Lee	Media MCC	Partner
Jin	Lee	LP	Oxonian venture
Andy	Lee	Investor	
David	Lee	CEO	WealthRyse
Li-Fen	Lee	CEO	Apeximmune Therapeutics Inc.
Shawn	Lee	Managing Partner	Lake Capital
Anthony	Lee		
John	Leonard		
Virginie	Leredu	Director	Senior Care 768
Gabriel	Levesque Tremblay		2048 Venture
Tom	Leyson	Director Investments	HSBC
Anita	Li		
Zhizhong	Li	Partner	Shiyu Capital
Luke	Li	CEO	Cugene, Inc.
Joanne	Li		
Charles	Li		AAVnergene
Iris	Li	Founder	New Frontier Enterprises
Jason	Lih	VP	Apeximmune Therapeutics Inc
Jamie	Lim		
Greg	Lim	Cofounder & CEO	WellBeings
Karen	Lin	CEO	Emotivo Health
Michaele	Linden Johnson	VP Strategic Partnerships	Lahjavidia
Cecilia	Lindgren	Venture Partner	Population Health Partners
Guosong	Liu	CEO	Neurocentria
Andrea	Liu	Investment Officer	The Li Family Office
Jamie	Liu	Director	Legend Capital
Karen	Liu	Partner	3E Bioventures Capital
Yan	Liu	Founder and CEO	Forward Clinical Solutions
Yue	Liu	CEO	Ab Studio Inc.
Joseph	Liu	Co-Founder	ArionBio
Dr. Daozhi	Liu	Founder, Managing Partner	Sunland Fund

Daozhi	Liu	Founder & Partner	Sunland Investment Management
Osamu	Lizuka		Medmain Inc
Michael	Louis	Partner	Silicon Valley Venture Growth Partners
Nina	Lu	Investor	DTC
Avery	Lu	Partner	Aventurine Capital Group
Sophia	Lu	Partner	Innouveaute
Georgia	Lu	Managing Partner	Magnet Ventures
Chongyang	Luo	COO	Coastar Therapeutics
Tyler	Luyben	Principal	Sixty Degree Capital
Gloria	Maceiko	CEO- Founder	Silicon Valley Advantage
Paulo	Machado	CEO/Investor	Health Innovation
Scott	Mader	CEO	AseptiScope
B. Dusty	Majumdar	CEO	PredxBio
Ramkumar	Mandalam	Consultant	Lahjavidia
William	Manson	Associate	VU Venture Partners
Mao	Mao	Director of BD and Licensing	LaNova
Christoph	Massner	Principal	Earlybird Venture Capital
Phillip	Masterson	Associate Director, Ventures	Cancer Research Horizons
John	Mattison	Chief Medical Information Officer	Arsenal Capital Partners
Nicholas	McBride	Director, Business Development	SIC Venture Studio
Nick	McBride		SK Venture Studio
Steve	McCloskey	CEO	Nanome
Timothy	McDonald	Partner	Guidon Partners
Kingsley	McGowan	Cofounder	WellBeings
Scott	McPhee	Partner	MQB Partners
Shreefal	Mehta	Entrepreneur in Residence	Columbia Tech Ventures
Saahil	Mehta		
Irie	Meltzer	VP Business Development	New Phase
Pedro	Mendez		
Matthias	Menne	CEO	HBOX Therapies GmbH
Greg	Merril	Executive Director	Chariot Biosciences
Pecho	Mevdes		Biotech R+D
Jon	Michaeli	Chief Commercial Officer	RT MicroDx
Alessandro	Migliara	Postdoc	UCSF
Chad	Miller	Co-Founder, Head of Research	Nosis Bio
Shahnaz	Miri	MD, CEO	Vision Neurology Inc.
Prasun	Mishra	Chairman	Wise Capitals
Mao	Miyamoto	CEO	M4
Nicola	Molinazzi	CTO	EZMEMS
Sayan	Mondal	CEO	NeuroLambda Therapeutics
Gregory	Montalbano	COO	MIDI
Deborah	Moorad	Founder: Venture Builder	JAX XII
Ralph	Morales III	Venture Partner	Aquillius Ventures
Megan	Morgan	Client Experience Specialist	JP Morgan
Brannon	Morisoli	SVP Credit	Ryan Credit Solution
Claire	Mortoni	Chief Financial Officer	ArthroLase
Katera	Mujadidi	Managing Director	Grikitis Group
Kevin	Mullenex	CEO & Co-Founder	IotaBEAM, Inc.
Erik	Musalem	Managing Partner	Sila-B
Afshin	Nadershahi	CEO	Stroma Medical
Suzanne	Nagy	Director	Spectrum
Sandy	Naidu	Managing Partner	Marathon Fund
Sonja	Nakasian	Founder	Epiveris
Hoyun	Nam	Director	VSPHarmtech Co., Ltd.
Ramani	Narayan	CO-Founder, COO	ThetaRho.ai
Sheeta	Nariani	GP & Founder	GLobal Health Impact Network & Fund
Rabab	Nasrallah	Principal	Earlybird Venture Capital
Subrat	Nayak	Founder	Vetty Inc.
Jean	Nehme	Strategic Advisor	FluidAI Medical
Annie	Ng		
Lucas	Ngoo	Co-founder	Carousell & CareSense.ai
Annie	Niederhofer	Investor	ACN
Andrew	Nimmich	Founder & CEO	Arterios
John	Nobile	Founder and CEO	New England Hemolytics Inc.
Gaurav	Nukala	Executive Consultant	J&J Innovative Medicine
Richard	O'Donnell		
Rachael	O'Meara	Partner	SIC Venture Studio
Felix	Oen	Co-Founder CEO	TikaHealth Limited
Raphael	Ognar	President & CEO, Co-founder	NKILT Therapeutics, Inc.
Manabu	Ohashi	Assitant General Manager	Marubeni America Corporation
Michael	Ostby	Vice President	JP Morgan Private Client
Heiko	Ott	CEO	Hottbio
Franky	Pan	Senior Investment Manager	Sino Biopharma Strategic Investment dept.
Pahini	Pandya	CEO	Panakeia Industries

Richard	Panico	Consultant	
Soyoung	Park	General Partner	1004 Vennture Partners
Eric	Park	Senior Principal	Bluepoint Partners
Shinyoung	Park	CEO	VSPHarmtech Co., Ltd.
Changsook	Park	BD Director	OPIS
Blake	Pate	Vice President, Investment	Bios Partners
Blake	Pate	Executive Vice President, Investment	Bios Partners
Hardik	Patel	CBO	Mobius
Bhavin	Patel	Head of Healthcare ECM	BTIG
Ed	Paxton	Founding Partner	Greyrock Ventures
Dexter	Pearson	Partner	Collage Venture Partners
Stuart	Penney	Senior Partner and Owner	PIR International
Taci	Pereira	CEO	Systemic Bio
Diana	Pignalosa	Head of Strategic Partnering	Debiopharm
Henry	Pittman	Managing Partner	GSC360
Bryan	Poltilove	Investment Committee	Altius BioVentures
Valeria	Povolotsky	Investment Expert	Quata Confidence Capital
Jonah	Probell	Managing Partner	Lexi Ventures
Pietro	Puglisi	Partner	Claris Ventures
Oleh	Pylyp	BD	inVerita
Julie	Qi	VP Business Development	AbboMax, Inc
Crystal	Qin	President & CEO	LaNova
Zhican	Qu	COB/CEO	Nanolattix
Annie	Quinn	Founder/Investor	Pacific West
Nevin	Ramanujan	General Partner	InnovateHealth Ventures
Duleek	Ranatunga	CEO	Pear Bio
Kerry	Rees		
Karim	ReFaey	Investment Associate	DigitalDx Ventures
Emilie	Rennie	Chief of Staff	ResVita Bio
Brian	Reynolds	CEO & Managing Partner	Chatham Capital
Chad	Rheault	Director of Operations & Product Dev.	Zepto Life Technology, Inc
John	Ricci	Managing Director	US Angels
Stephane	Richard	CEO	GEN2X / Largo Tx
David	Rogers	Principal	Pac West
Kathryn	Rose	CFO	Think-Now
Marci	Rosenfeld	Executive Director	JP Morgan Advisors
Malcolm	Rosenthal	CEO	Rosechem Group
Jermaine	Ross	CEO	Alleo Labs
Maggie	Rougier-Chapman	Founder & President	Footprint BioAdvisors
Michael	Rudman	Investor	Actiphone
Paul	Russo	CEO	K2X
Rory	Ryan	CEO	PentaBind
Anthony	Ryan	Chief Executive Officer	Brisbane Economic Development Agency
Nayeon	Ryoo		MediaiPlus
Jeyla	Sadikova	Co-Founder	Illumicell AI
Ed	Said	CEO	Teledental.com
Rahul	Saikia	Head of Portfolio Investments	Shore Pharma Venturas LLC
Wiriya	Sakcharoenchai	Investment associate	Disrupt Impact Fund L.P.
Naveed	Salman	Principal	Cheshire Peak Investments
Philipp	Sander	Investment Analyst	IndieBio/SOSV
Vladik	Sandler	CEO and Founder	Hemogenyx
Alexis	Sandler	General Counsel	Hemogenyx
Minnie	Sarwal	Founder	UCSF
Rose	Satz		AIB
Rosemarie	Savino		Vannadium
Mary	Schaheen	President	Prevail Partners LLC.
Hajo	Schiewe	VP, Head of West Coast Business Dev.	Evotec
Paul	Schmidt	Angel	Alexion Rare Disease
Ryan	Schmitzer	Associate	Draper University Ventures
Jonathan	Schmolke	Membership Director	Keiretsu Forum
Joseph	Schneier	CEO	Circle Engage
Rajub	Schubert	CEO	Cellstamp
Tricia	Schumann	Principal	Health Innovation Capital
Eric	Schuur	CEO	Hepatx Corporation
Dan	Sclafani		
Tony	Seaman		Compandia Health
Sara	Secall	Partner	Inveready Asset Management
Frank	SEO		FluidAI
Sonia Maryam	Setayesh	Investment Partner	Civilization Ventures
Mila	Shabalina	Intern/Company liaison, Angel Investor	Wealthing VC Fund
wendy	shao	Partner	Material Impact
Himanshu	Sharma	Healthcare Growth Investor	JP Morgan
Brett	Shealy	Executive Director	JPMorgan
Khurram	Sheikh	Founder, Chairman & CEO	KINS Technology Group

Ron	Shigeta	Principal	laccelerate.tech
Ethan	Shin	Managing Director	KB Investment
Tsvi	Shmilovich	CEO	EZMEMS
Natasha	Shtraizent	CEO	Frezent Biological Solutions
Scott	Shu	VP of Global Business Dev.	EverBridge MedTech
Terry	Shuai	CFO	Blissbio
Mridul	Shukla	Head of Regulatory, Gene Therapy	Poseida
Alita	Singer		
Manny	Singh	CEO-Founder	SensTek
Rohit	Singh	Managing Director	VBW Holdings
Raj	Singh	General Partner	Z21 Ventures
Lyle	Small	CEO /Founder	Lahjavidia
Yauheni	Solad	Managing Partner	Dalos Partners
Tom	Solitario	Technology Scout for Corporate Venture	Tom, Inc.
Ciro	Spedaliere	Partner	Claris Ventures
John	Stankus	COO	Resurge Therapeutics
Christopher	Steele		
Andrew	Steinsapir	Director	Deerfield
Andrew	Sternlicht	CEO and Founder	Aisa Pharma, Inc.
William	Stilley	CEO	Advocate
Richard	Stokvis	Managing Director	Boa Healthcare Ltd
Zahava	Stroud	Angel	Family office
Maylan	Studart-Anders	Wealth Advisor	Merrill Lynch
Chloe	Sun	SVP	BBR
Jie	Sun	CEO	ChemT
Sophie	Sun	Partner	KP Healthcare Partners
Wei	Sun	Executive Vice President, Investment	Sunland Fund
Cephas	Sund		Hibiscus Capital Management
Krissy	Sutton	VP	Ideatravel
Tom	Swanson		
Michael	Swartzburg	CFO	Independent
David	Swintosky	Founder	Dunning Capital
Zikria	Syed	CEO	PatientWing
Seiya	Takahashi	Venture Partner	Hike Ventures
Bharath	Takulapalli	Founder & CEO	SPOC Proteomics Inc
Andrew	Tansil	Founder	Elevated Holdings Group
Zhen	Tao	Partner	Bridge Link Capital
Michal	Tavrovsky	Co-founder	MenHealth
Michael	Taylor	VP Business Development	SIC Venture Studio
Dayu	Teng	Venture Partner	AllyBridge Group
Cheryl	Teo	Senior Associate	MassMutual Ventures
Alexandre	Thermet	Sr Manager Business Development	Bio-Rad Laboratories
Naranpat	Thitipattakul	Partner	Disrupt Impact Fund L.P.
Susan	Thomas	Principal	Endpoint Communications
Vivekananda	Thunga	Vice President	XCaliber Health
Anthony	Tijerino	Director	TMF
Nonna	Titulauri	VP of Deal Sourcing	Simon School Venture Fund
Dirk	Tomandl	CTO, Cofounder	InFocus Therapeutics
Paola	Torre	VC Analyst	Aquilius Ventures
Joel	Tovel	Software Testing Engineer	Cubic
Gabriel	Tremblay	Deal Maker	2048 VC
Mikael	Trollsas	CEO	Resurge Therapeutics Inc.
Kristina	Trujillo	CEO	T-Neuro Diagnostics
Mike	Trujillo	CEO	T-Neuro Diagnostics
Frank	Truslow	Advisor to Life Sciences Companies	Altius Partners
Vincent	Tse	Executive Director of Staff and Strategy	HiFiBio Therapeutics
Silvan	Tuerkcan	Senior Analyst	Citizens JMP
Ari	Tulla	CEO & Founder	Elo Health
Varun	Turlapati	Owner	Astute Crew LLC
Bernie	Tyson	Principal	Collage Venture Partners
Vishal	Vachani	Investor	Zen Biz
Evelina	Vågesjö	CEO	Ilya Pharma
Laurent	Van Lerberghe	Managing Partner	Keles digital health
Cleo	Vee	Founder and Investor	Epi
Johana Carolina M	Vega Leonel	Owner	Astute Crew LLC
S	Velaga		
Matt	Venturi	CEO	ClearingBid
Ajay	Vishwakarma		
Christa	Vitrouil	COO	InFocus Therapeutics
Tom	Vogelsong	Startup Scout	K2X Capital
Anna	Von Wendorff	Founder	Aclarity Health
Dongxue	Wang	VC	Gudu Medical PTE
Sally	Wang Liang	Partner	Highlight Capital
Audrey	Warner	Partner	Tiger Gene

Spencer	Waspi	Vice President	JPMorgan
Mike	Watson	CEO	Miruminvest
Phil	Wei	President	Darsheng Tech
Keene	Wei	CEO	VitsGen
Changhao	Wei	Senior Vice President	Co-win Ventures
Andrew	Wells	Partner, Patent Attorney	HGF
Norman	Wen	CEO	Soterya, Inc.
Leon	Wert Lamas	Head of Global BD	Vibrant Tx
Jamie	White	Investor Advisor	
Chris	Wigley	Venture Partner	Population Health Partners
Ben	Williams	Angel Investor	TiE Angel Houston
Randy	Williams	Founder & CEO	kelRETSU FORUM
Ryan	Witt	Angel	Tech Coast angels
Geoff	Workman	Managing Partner	Capital Ideas Holdings
Wei	Wu	Senior Director	Johnson & Johnson
Jim	Wu	Founder	SaniMed Science Group
Elizabeth	Wu	VP International Affairs	Nanolattix
Jeane	Xi	EVP, R&D	Cugene, Inc.
Nate	Xia	Principal	Sixty Degree Capital
Jun	Xiang	Board Director	Bluewater Investments Holding Ltd.
Lily	Xie	Founder	VentureLenses
Simon	Xiong	CEO	3DMed Diagnostics
Lisa	Xu	Venture Partner	Tailwinds Venture
John	Xu	President	Biorich international
Wenfeng	Xu	President and CSO	Chantibody Therapeutics Inc
Jenna	Xu		Cugene Inc
Eddie	Yang	Principal	Deerfield Management
Yieyie	Yang	Partner	Finnegan Henderson Law Firm
Haichen	Yang	Vice President, Clinical Research	Amicus Therapeutics
Cheryl	Yang	VP of Business Development	CStone Pharmaceuticals
Yang	Yang	Head of Business Development	WestGene Biopharma
Paul	Yaswen	Managing Director	Third Pillar Associates
Gloria	Yee	CIO, Founder, Professor	College of Marin
Jun	Yin	Associate	Fortera Capital
Rumi	Yokota	Associate	DigitalDx Ventures
Chuck	Yoo	Executive Vice President for Research	Korea University
Jami	Youmans	General Partner	InnovateHealth Ventures
Paul	Young	Founder & CEO	Nutmeg
Kristine	Yu	Partner	Tamer Life Sciences
Ed	Zapanta	Developer/Investor	HolospaceX
Ronalee	Zarate-Briyani	Cofounder	WellBeings
Rachel	Zayas		AGED DX
Sean	Zeng	Global Hedge Fund of Business Dev.	4B Technologies
Shelby	Zhang	Investment Director	Vertex Growth Fund
Wei	Zhang	Partner	Fortunatus Capital
Jimmy	Zhang	Director	BioVenator
Han	Zhang	CEO	Zepto Life Technology, Inc
Dan	Zhang		
Shiqing	Zhang	Senior Investment Manager	Sino Biopharma Strategic Investment dept.
Eva	Zhang		
Haoxin	Zhang	CEO	OpenMinds AI Medical
Kate	Zhang	Venture partners	Tailwinds VC
Adam	Zhao	Partner	Anlongmed
Jonathan	Zheng	Strategic Initiatives	Ouros Ventures
Kelly	Zhou	CSO	AbboMax, Inc
Yu	Zhou	Co-founder	94 Biotherapeutics
Katie	Zhu		



Big Idea
CONNECTpreneur

**WORLDS LARGEST VIRTUAL
MONTHLY INVESTOR PITCH EVENT**

REGISTER NOW FOR

January 30th

[Click Here](#)



VIRTUAL AND IN-PERSON

CALL FOR PRESENTERS

Unprecedented
**Networking
sessions**
before, during, and
after each event

Free lifetime
admission
to all
CONNECTpreneur
Forums

Post-event recap to
**206k business
leaders**
in our Community

[CLICK HERE FOR
THE IN-PERSON
BROCHURE](#)

[CLICK HERE FOR
THE VIRTUAL
BROCHURE](#)

Get funded with our



Private Investor Platform



One of the nations largest investor communities of 4,500+ HNW/UHNW private investors, angels, family offices, investment groups, and small institutional investors.

**Exclusive,
cost effective,
& reliable**

**Vetted, qualified,
accredited
Investors**

**We
guarantee
our results**

[View the full
brochure here](#)

Tien Wong
CEO
twong@opus8.com

Skylar Rallison
Community Manager
srallison@opus8.com

DRIVING DIGITAL INNOVATION WITH MEANINGFUL OUTCOMES



Modus Create is an end-to-end digital consulting firm. We bring multiple integrated skill sets and methodology expertise across software, product, and commercial platform domains. Our clients experience a boutique feel on an enterprise scale.

Our Practices and Offerings

DIGITAL STRATEGY

Making intelligent decisions about investments in technology.

PRODUCT DEVELOPMENT

Building and enabling business-aligned applications that deliver stakeholder and customer value.

PLATFORM & CLOUD

Adopt a modern platform mindset, with scalable and secure architectures, tooling, and systems to increase quality and speed.

DIGITAL OPERATIONS

Operationalize collaboration, drive alignment in a single system of truth, and adopt modern methodologies for teamwork.

All four practice areas are powered by **AI & DATA** expertise throughout



Whether you're looking to innovate, scale, or transform, our team brings the right methodology and skill sets to drive your success.

Let's build the future together.
Contact us today to get started!



CONNECT with us!

